What patellofemoral OA feels like and who it affects

The pain usually builds quietly. Going downstairs becomes something to dread. Sitting through a film or a long car journey leaves the knee aching by the end. Squatting down — even briefly — produces a dull, grinding discomfort behind the kneecap. These are the hallmarks of patellofemoral osteoarthritis (PFOA): a recognised condition affecting the joint between the patella and the femur, distinct from the more commonly discussed tibiofemoral (inner or outer compartment) knee arthritis.

Unlike an acute ligament tear or a sudden cartilage injury, PFOA tends to develop gradually — often over months or years — driven by factors such as quadriceps weakness, imbalance in the vastus medialis oblique (VMO), and subtle changes in how the kneecap tracks in its groove. Anterior knee pain is the defining symptom, reliably aggravated by activities that increase patellofemoral load: stairs, squatting, cycling, and prolonged sitting (sometimes called the 'theatre sign').

One important nuance: the degree of pain does not map neatly onto the extent of structural change visible on imaging. Mild cartilage changes can produce significant symptoms; more advanced imaging findings are sometimes relatively quiet. Structural evidence alone is not the whole picture.

Most people reading this will have already tried rest, over-the-counter pain relief, and perhaps some exercises — and found that the pain keeps returning. This article covers the three broad stages of management when self-care has not been enough: structured conservative care, injection-based options, and — where those are exhausted — surgical pathways.

Why exercise and weight management come first

Quadriceps strengthening — with particular focus on the VMO — sits at the top of both NHS and AAOS guidance for PFOA, and for good reason: restoring muscle support around the patella is one of the most direct ways to reduce the abnormal load that drives cartilage breakdown.

This phase often feels counter-intuitive. Pain is present, and the instinct is to protect the joint by doing less. The evidence points the other way. A combination of targeted muscle-strengthening and general cardiovascular exercise is recommended even when activity is initially uncomfortable — the underlying principle is graded loading: starting at a level the joint can tolerate, then progressively building from there, guided by a physiotherapist.

Weight management works alongside this. Every kilogram removed reduces compressive force on the patellofemoral joint by a multiple of that load during activities such as stairs and squatting. Even modest weight reduction can produce a clinically meaningful difference in symptoms; diet and physical activity together are the recommended route.

The conservative tier is broader than exercise alone. Physiotherapy should be structured and goal-directed — not a handful of home exercises handed over at a single appointment. Topical NSAIDs applied directly to the knee, or oral anti-inflammatory medication, can help manage pain during the active rehabilitation phase. Orthotics and bracing are sometimes used to support patellar tracking; activity modification — temporarily avoiding the specific movements that provoke the most pain — allows the programme to continue without repeated flare-ups.

Duration and consistency are what turn this into a genuine trial. Dipping in and out of exercises for a few weeks does not constitute a fair test of conservative care. If pain persists or worsens despite a sustained, structured programme, specific clinical and imaging signals indicate that specialist review is the appropriate next step.

Signs that conservative care needs a rethink

Three broad categories of signal suggest that conservative care alone is no longer sufficient — and that a specialist assessment is the logical next step.

Symptoms that have not resolved

Anterior knee pain that persists or continues to worsen after a sustained, structured programme — typically several weeks of guided physiotherapy, targeted strengthening, and consistent activity modification — is the primary clinical marker. Night pain deserves particular attention: discomfort that disturbs sleep or occurs at rest is a red-flag symptom that should prompt earlier specialist review, regardless of how recently conservative care was begun.

Functional limitation affecting daily life

Difficulty managing stairs, discomfort following prolonged sitting, or an inability to return to work or recreational activity despite completing a structured programme all indicate that the condition is limiting function in a way that conservative measures have not adequately addressed.

What imaging can add at this stage

MRI is the appropriate investigation when escalation is being considered, because it provides information that X-ray cannot. Plain X-ray and CT contribute little to patellofemoral cartilage assessment unless disease is very advanced or surgical planning is underway. MRI identifies the size, depth, and location of cartilage damage with precision. A defect exceeding 1 cm carries a recognised risk of progressive deterioration and is a key structural escalation signal — even in cases where current symptoms feel relatively manageable. That said, a smaller defect causing severe functional limitation may equally justify escalation; defect size and symptom severity are both inputs, and they do not always point in the same direction.

When one or more of these criteria apply, an injection consultation — a structured clinical review combining examination, imaging assessment, and individualised treatment planning — is the appropriate next step.

What happens at an injection consultation

The clinician assesses the knee directly before any injectable option is discussed. This means a hands-on physical examination — testing range of motion, patellar tracking, joint-line tenderness, and the response to specific loading manoeuvres — combined with a review of any imaging already obtained. If no MRI has been done, or if the existing scans are outdated, an ultrasound assessment may be arranged at the same appointment; ultrasound can confirm the degree of synovitis and guide the injection itself.

Only once that clinical picture is assembled does the agent discussion begin — and it should be a discussion, not a default. Corticosteroid is appropriate where there is active synovitis; hyaluronic acid addresses joint lubrication; Arthrosamid® polyacrylamide hydrogel acts as a durable intra-articular scaffold, with evidence from a 2022 study demonstrating reduction in patellofemoral bone marrow lesions following a single injection. ChondroFiller® collagen scaffold, a CE-marked outpatient procedure, recruits the patient's own cells to support cartilage regeneration and is suited to identifiable focal defects. PRP and other biologics require imaging review to justify their use in the individual case. A clinician proposing the same agent regardless of presentation is not following best practice.

A well-structured consultation concludes with an itemised plan — the proposed agent, its rationale, and the clinician who will perform the procedure — alongside a scheduled follow-up, typically at around six weeks for most injectable treatments. The consultation is also the point at which the clinician maps the patient's broader trajectory: whether injection represents a standalone intervention or one step within a longer joint-preservation plan.

The injectable options and what the evidence shows

Each injectable agent available for patellofemoral OA works through a different mechanism — which is why the choice of agent matters as much as the decision to proceed. Direct RCT evidence specifically in isolated PFOA, as distinct from broader knee OA populations, remains limited across all categories, so agent selection should always be anchored to the individual's imaging findings and symptom profile rather than applied as a protocol.

Corticosteroids

Corticosteroids suppress local inflammatory mediators, producing relatively rapid pain relief when active synovitis is present. They are not disease-modifying — the underlying cartilage is unaffected — and repeated injections may accelerate local tissue changes over time. Their clearest role is during acute inflammatory flares, where short-term relief can allow a physiotherapy programme to continue.

Hyaluronic acid (viscosupplementation)

Hyaluronic acid restores the viscoelastic properties of synovial fluid that degrade as cartilage breaks down. Regimens range from a single injection to courses of up to five weekly injections. A systematic review found no consistent superiority of multi-injection schedules over single-injection formulations, making the simpler regimen increasingly preferred on grounds of both convenience and reduced complication risk.

Arthrosamid® polyacrylamide hydrogel

Composed of 2.5% cross-linked polyacrylamide in water, Arthrosamid® adheres to the synovial membrane as a durable intra-articular scaffold rather than being absorbed or metabolised. A 52-week prospective study demonstrated significant improvement in knee OA symptoms. PFOA-specific evidence includes a 2022 study (Maulana, Cole & Lee) reporting reduction in patellofemoral bone marrow lesions following a single injection — a structural signal that distinguishes it from purely symptomatic agents.

ChondroFiller® collagen scaffold

ChondroFiller® occupies a distinct regenerative category. As a CE-marked collagen scaffold, it is injected directly at the defect site, where it recruits the patient's own cells to support cartilage regeneration — a fundamentally different mechanism from space-filling or lubricating agents. It is delivered as an outpatient procedure without general anaesthesia, and is most suited to identifiable focal cartilage defects confirmed on imaging.

PRP and biologics

Platelet-rich plasma concentrates growth factors from the patient's own blood and delivers them intra-articularly to modulate the local inflammatory environment and promote tissue repair. The evidence base is heterogeneous: some studies suggest benefit where an inflammatory or early degenerative component is present on imaging, but results vary by preparation method and patient selection. Like all injectable agents, it should follow a thorough imaging review rather than be applied generically.

Surgery as the last rung: when injections are no longer enough

Surgery sits at the far end of the pathway deliberately. Patellofemoral arthroplasty and total knee replacement are options reserved for patients in whom conservative management and multiple non-surgical interventions have genuinely failed to provide adequate relief — not a default or inevitable destination.

The threshold is not fixed. Symptom severity, degree of functional limitation, what imaging shows, and a patient's own goals all inform that decision. Crucially, failing to respond to one injection course does not automatically place a patient on a surgical pathway. A re-assessment of conservative and injection options — a different agent, a structured return to physiotherapy, or a combination approach — is typically the appropriate next step before surgery enters the conversation.

One question worth raising directly with a specialist: what proportion of patients at your stage go on to need surgery? The honest answer will acknowledge real uncertainty. Data on conversion rates from failed injection therapy to surgery in isolated PFOA comes largely from mixed knee OA populations, and reliable condition-specific figures are not yet established — which is itself a useful piece of information when weighing options.

The broader picture is genuinely reassuring. Most people with patellofemoral OA manage their symptoms successfully without ever reaching the surgical rung, particularly when the conservative and injection stages are approached in sequence and with appropriate clinical input. For anyone at the escalation-signal stage — persistent anterior knee pain, meaningful functional limitation, or progressing imaging findings — the most useful next step is a structured specialist assessment that maps remaining options clearly, not one that presupposes a surgical outcome.

1. [1] Joint injection. https://en.wikipedia.org/?curid=1425459 https://en.wikipedia.org/?curid=1425459
2. [2] Patellofemoral pain syndrome. https://en.wikipedia.org/?curid=12033023 https://en.wikipedia.org/?curid=12033023